Navarro J T, Hernández J A, Ribera J M, Sancho J M, Oriol A, Pujol M, Millá F, Feliu E
Hematology-Hemotherapy Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Haematologica. 1998 Nov;83(11):998-1000.
The threshold for prophylactic platelet transfusions has been classically established at 20,000/microL. In 48 patients with de novo acute myeloblastic leukemia (AML) we analyzed the effect of reducing the threshold for prophylactic platelet transfusion from 20,000/microL (group A) to 10,000/microL (group B) after induction and consolidation chemotherapy.
Forty-eight adult patients with de novo AML diagnosed in a single institution in a nine year period were enrolled in the study. Between January 1989 and December 1993 the patients received prophylactic platelet transfusions when their platelet count was below 20,000/microL (group A), and from January 1994 to March 1998 prophylactic platelet transfusions were indicated below 10,000/microL or between 10,000/microL and 20,000/microL if there was any consumption factor.
The mean number (SD) of platelet transfusions during induction was 8.4 (5.3) in group A and 8.5 (5.5) in group B; and during consolidation 4.7 (3.4) in group A and 4.6 (3.8) in group B (p = n.s.). Excluding the cases with consumption factors from the analysis, group B patients required 34% fewer transfusions during induction and 15.5% fewer during consolidation (p = 0.04). There were no differences between groups regarding major bleeding episodes.
Our data show that the threshold for prophylactic platelet transfusion can be safely set at 10,000 microL during induction and consolidation chemotherapy for adult patients with de novo AML.
预防性血小板输注的阈值传统上设定为20,000/微升。我们分析了48例初发急性髓细胞白血病(AML)患者在诱导和巩固化疗后将预防性血小板输注阈值从20,000/微升(A组)降至10,000/微升(B组)的效果。
本研究纳入了9年间在单一机构确诊的48例初发AML成年患者。1989年1月至1993年12月期间,患者血小板计数低于20,000/微升时接受预防性血小板输注(A组);1994年1月至1998年3月期间,血小板计数低于10,000/微升或存在任何消耗因素且血小板计数在10,000/微升至20,000/微升之间时给予预防性血小板输注。
诱导期A组血小板输注的平均次数(标准差)为8.4(5.3)次,B组为8.5(5.5)次;巩固期A组为4.7(3.4)次,B组为4.6(3.8)次(p值无统计学意义)。分析时排除有消耗因素的病例,B组患者在诱导期所需输注次数减少34%,巩固期减少15.5%(p = 0.04)。两组在严重出血事件方面无差异。
我们的数据表明,对于初发AML成年患者,在诱导和巩固化疗期间预防性血小板输注阈值可安全设定为10,000微升。